SCHEMBL29308274

SCHEMBL29308274

C=C(CNC(=O)C(C)NC(=O)CNC(=O)CNC(=O)CNC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C1CCCN1)N1CCCC1C(=O)NCC(=O)O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 1/20 0.34
▸ MAPK9 P45984 1/20 0.34
▸ MAPK10 P53779 1/20 0.34
▸ KEAP1 Q14145 1/20 0.34
▸ OXTR P30559 3/20 0.33
▸ FAP Q12884 1/20 0.33
▸ APLNR P35414 1/20 0.32
▸ NMUR2 Q9GZQ4 1/20 0.32
▸ NMUR1 Q9HB89 1/20 0.32
▸ NAA50 Q9GZZ1 1/20 0.32
▸ AVPR2 P30518 2/20 0.32
▸ AVPR1A P37288 2/20 0.32
▸ AVPR1B P47901 2/20 0.32
▸ TERT O14746 1/20 0.32
▸ CALCRL Q16602 1/20 0.32
▸ KDM1A O60341 1/20 0.32
▸ MAOB P27338 1/20 0.32
▸ KDM5A P29375 1/20 0.32
▸ KDM1B Q8NB78 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22018362 0.93 FAP (0.38) MAPK8MAPK9MAPK10KEAP1OXTR
SCHEMBL23871517 0.93 FAP (0.38) MAPK8MAPK9MAPK10KEAP1OXTR
SCHEMBL29308497 0.91 FAP (0.36) MAPK8MAPK9MAPK10KEAP1OXTR
SCHEMBL26391856 0.89 APLNR (0.38) MAPK8MAPK9MAPK10KEAP1OXTR
SCHEMBL29308489 0.88 NAA50 (0.39) MAPK8MAPK9MAPK10KEAP1OXTR
SCHEMBL29308258 0.86 CTSD (0.34) MAPK8MAPK9MAPK10KEAP1OXTR
SCHEMBL22922838 0.86 MAPK8 (0.43) MAPK8MAPK9MAPK10KEAP1APLNR
SCHEMBL29308229 0.86 CTSD (0.37) MAPK8MAPK9MAPK10KEAP1OXTR
SCHEMBL29308379 0.85 FAP (0.32) KEAP1FAP
SCHEMBL22922802 0.85 NAA50 (0.42) MAPK8MAPK9MAPK10KEAP1OXTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient YUYU PHARMA, INC. (KR) 2024-07-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient VIP, IAPP, NGLY1 MAPK8 3503/4885MAPK9 1766/4885MAPK10 2677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback